Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of Lazertinib Tablet Formulations in Healthy Adults
NCT05896683Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- May 2023
- Primary completion
- Sep 2023
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of lazertinib in non-small cell lung cancer (NSCLC) (4 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Maximum Observed Plasma Concentration and Area Under the Plasma Concentration-time Curve. Started May 2023; status: completed.
02
Drugs
lazertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05896683.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05896683.